Charles River Laboratories International (NYSE:CRL) Shares Down 3.7% – Here’s What Happened

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) were down 3.7% during mid-day trading on Monday . The stock traded as low as $161.53 and last traded at $167.4580. Approximately 253,253 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 967,783 shares. The stock had previously closed at $173.89.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CRL. Evercore raised their target price on Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Wall Street Zen downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. JPMorgan Chase & Co. upped their price objective on Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. Finally, UBS Group lifted their target price on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $206.15.

Charles River Laboratories International Stock Up 0.8%

The company has a market cap of $8.37 billion, a price-to-earnings ratio of -57.29, a PEG ratio of 2.11 and a beta of 1.61. The business has a fifty day moving average of $172.46 and a two-hundred day moving average of $181.66. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.33 by $0.06. The company had revenue of $994.23 million for the quarter, compared to analyst estimates of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.Charles River Laboratories International’s quarterly revenue was down .8% compared to the same quarter last year. During the same period last year, the company earned $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Charles River Laboratories International

A number of large investors have recently added to or reduced their stakes in CRL. Tema Etfs LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter valued at about $26,000. Rothschild Investment LLC raised its position in shares of Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after purchasing an additional 84 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new position in Charles River Laboratories International in the 3rd quarter valued at about $31,000. Los Angeles Capital Management LLC acquired a new stake in Charles River Laboratories International in the 4th quarter worth about $42,000. Finally, Sfam LLC purchased a new stake in Charles River Laboratories International during the 4th quarter worth approximately $43,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.